leisure time -WSS

leisure time

author：explore 2025-10-01 17:20:07 - browse：929

A medical device to treat below-the-knee chronic limb-threatening ischemia, Esprit BTK resorbable scaffold, is shown consisted of pieces of geometric shapes that lined up into a pipe on a blue background — health tech coverage from STAT — Cardiovascular doctors are optimistic about Abbott’s new below-knee stent that disappears into the blood vessel’s walls over the course of three years. Courtesy Abbott

An Abbott device that failed in heart disease patients is getting a new life in patients with severe vascular disease.

The device is a below-knee stent that widens clogged blood vessels, and then vanishes into the vessel’s walls over the course of three years. It also delivers a drug that prevents scar tissue from forming — a common risk factor with traditional metal stents that further narrow the vessel.

Abbott’s first dissolvable stent, for coronary artery disease, received Food and Drug Administration approval in 2016. But the company voluntarily pulled the product from the market just over a year later due to “low commercial uptake.” The device also received mixed results in clinical trials.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How one medical school became remarkably diverse
Next article： State Dept. review finds Biden bears some blame for Afghanistan failures

WSS

First over

Streamlined flu vaccines recommended by FDA advisory panel

Activists slam private health insurers over coverage restrictions

Supreme Court strikes down use of affirmative action

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Harvard's David Sinclair gets blowback over aging

Wikipedia

leisure time

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

hotspot

Cancer drug shortages should be causing more outrage

The untold story of TV’s first prescription drug ad

Affirmative action in medical school literally saved lives

The high cost of giving birth even with insurance

BioMarin wins approval for gene therapy to treat hemophilia A

Harvard's David Sinclair gets blowback over aging

Medicare details structure of new drug price negotiation program

What does generative AI mean for health care? We asked experts

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Pregnant women don't need prenatal multivitamins, study concludes

focus

Drug repurposing or repositioning? The language matters

Florida health officials providing scant details on measles cases

Readout Newsletter: BridgeBio, Akero, and human embryo models

Guidelines to prevent youth baseball injuries need more muscle

In age of alternative facts, a scholarly course on calling out crap

Florida health officials providing scant details on measles cases

explore

Wikipedia

focus

leisure time